BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35063636)

  • 1. Global management of brain metastasis from renal cell carcinoma.
    Pierrard J; Tison T; Grisay G; Seront E
    Crit Rev Oncol Hematol; 2022 Mar; 171():103600. PubMed ID: 35063636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic Radiation Therapy for Renal Cell Carcinoma Brain Metastases in the Tyrosine Kinase Inhibitors Era: Outcomes of 120 Patients.
    Klausner G; Troussier I; Biau J; Jacob J; Schernberg A; Canova CH; Simon JM; Borius PY; Malouf G; Spano JP; Roupret M; Cornu P; Mazeron JJ; Valéry C; Feuvret L; Maingon P
    Clin Genitourin Cancer; 2019 Jun; 17(3):191-200. PubMed ID: 30926219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma.
    Verma J; Jonasch E; Allen PK; Weinberg JS; Tannir N; Chang EL; Mahajan A
    Am J Clin Oncol; 2013 Dec; 36(6):620-4. PubMed ID: 22892430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic renal cell carcinoma to the brain: optimizing patient selection for gamma knife radiosurgery.
    Stenman M; Benmakhlouf H; Wersäll P; Johnstone P; Hatiboglu MA; Mayer-da-Silva J; Harmenberg U; Lindskog M; Sinclair G
    Acta Neurochir (Wien); 2021 Feb; 163(2):333-342. PubMed ID: 32902689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidiscipline Immunotherapy-Based Rational Combinations for Robust and Durable Efficacy in Brain Metastases from Renal Cell Carcinoma.
    Lee HW
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34208157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies.
    Zaorsky NG; Lehrer EJ; Kothari G; Louie AV; Siva S
    Eur Urol Oncol; 2019 Sep; 2(5):515-523. PubMed ID: 31302061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic radiosurgery for the treatment of melanoma and renal cell carcinoma brain metastases.
    Lwu S; Goetz P; Monsalves E; Aryaee M; Ebinu J; Laperriere N; Menard C; Chung C; Millar BA; Kulkarni AV; Bernstein M; Zadeh G
    Oncol Rep; 2013 Feb; 29(2):407-12. PubMed ID: 23151681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Factors for Survival of Patients With Synchronous or Metachronous Brain Metastasis of Renal Cell Carcinoma.
    Choi SY; Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
    Clin Genitourin Cancer; 2017 Dec; 15(6):717-723. PubMed ID: 28552571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
    Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
    J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases.
    Sperduto PW; Deegan BJ; Li J; Jethwa KR; Brown PD; Lockney N; Beal K; Rana NG; Attia A; Tseng CL; Sahgal A; Shanley R; Sperduto WA; Lou E; Zahra A; Buatti JM; Yu JB; Chiang V; Molitoris JK; Masucci L; Roberge D; Shi DD; Shih HA; Olson A; Kirkpatrick JP; Braunstein S; Sneed P; Mehta MP
    Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):845-853. PubMed ID: 29976497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors affecting survival in 37 consecutive patients undergoing de novo stereotactic radiosurgery for contiguous sites of vertebral body metastasis from renal cell carcinoma.
    Sellin JN; Reichardt W; Bishop AJ; Suki D; Rhines LD; Settle SH; Brown PD; Li J; Rao G; Chang EL; Tatsui CE
    J Neurosurg Spine; 2015 Jan; 22(1):52-9. PubMed ID: 25360530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival benefit with resection of brain metastases from renal cell carcinoma in the setting of molecular targeted therapy and/or immune therapy.
    Huntoon K; Damante M; Wang J; Olencki T; Elder JB
    Curr Probl Cancer; 2022 Apr; 46(2):100805. PubMed ID: 34836657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation therapy in the management of brain metastases from renal cell carcinoma.
    Doh LS; Amato R; Paulino AC; Teh BS
    Oncology (Williston Park); 2006 May; 20(6):603-13; discussion 613, 616, 619-20 passsim. PubMed ID: 16773845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control.
    Sheehan JP; Sun MH; Kondziolka D; Flickinger J; Lunsford LD
    J Neurosurg; 2003 Feb; 98(2):342-9. PubMed ID: 12593621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiotherapy for Brain Metastases From Renal Cell Carcinoma in the Targeted Therapy Era: The University of Rochester Experience.
    Bates JE; Youn P; Peterson CR; Usuki KY; Walter KA; Okunieff P; Milano MT
    Am J Clin Oncol; 2017 Oct; 40(5):439-443. PubMed ID: 25730604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting the Risk of Developing New Cerebral Lesions After Stereotactic Radiosurgery or Fractionated Stereotactic Radiotherapy for Brain Metastases from Renal Cell Carcinoma.
    Rades D; Dziggel L; Blanck O; Gebauer N; Bartscht T; Schild SE
    Anticancer Res; 2018 May; 38(5):2973-2976. PubMed ID: 29715126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain metastases from renal cell carcinoma: Effects of novel systemic agents on brain metastasis outcomes.
    Ressler HW; Cramer CK; Isom S; McCormack M; Ruiz J; Xing F; Li W; Whitlow CT; White JJ; Laxton AW; Tatter SB; Chan MD
    Clin Neurol Neurosurg; 2024 Mar; 238():108191. PubMed ID: 38422744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving the Prognostic Value of Disease-Specific Graded Prognostic Assessment Model for Renal Cell Carcinoma by Incorporation of Cumulative Intracranial Tumor Volume.
    Ali MA; Hirshman BR; Wilson B; Schupper AJ; Joshi R; Proudfoot JA; Goetsch SJ; Alksne JF; Ott K; Aiyama H; Nagano O; Carter BS; Chiang V; Serizawa T; Yamamoto M; Chen CC
    World Neurosurg; 2017 Dec; 108():151-156. PubMed ID: 28754641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome of stereotactic radiosurgery for central nervous system metastases from renal cell carcinoma.
    Seastone DJ; Elson P; Garcia JA; Chao ST; Suh JH; Angelov L; Rini BI
    Clin Genitourin Cancer; 2014 Apr; 12(2):111-6. PubMed ID: 24331575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of stereotactic radiosurgery dose on control of cerebral metastases from renal cell carcinoma.
    Rades D; Huttenlocher S; Gebauer N; Hornung D; Trang NT; Khoa MT; Schild SE
    Anticancer Res; 2015 Jun; 35(6):3571-4. PubMed ID: 26026128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.